Press Release Service
Vertex and CRISPR Therapeutics Complete Submission...
Apr. 3, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
CRISPR Therapeutics
Main focus: Gene editing for the treatment of genetic diseases and cancer
Company stage: Clinical
Diseases: Sickle cell disease, beta-thalassemia, multiple myeloma, haematological malignancies, solid tumours, Type 1 diabetes mellitus, Glycogen storage disease type 1a (GSD 1a), duchenne muscular dystrophy, myotonic dystrophy type 1, cystic fibrosis
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:CRSP)
Location: Zug, Switzerland and Cambridge, MA, USA
Website: http://www.crisprtx.com/
Pipeline: http://www.crisprtx.com/programs/pipeline
Partners: Vertex Pharmaceuticals, ViaCyte, Nkarta Therapeutics, Capsida Biotherapeutics, CureVac, KSQ Therapeutics, Anagenesis Biotechnologies, ProBiogen
CRISPR Therapeutics is a clinical-stage genome-editing company primarily working with haemoglobinopathies, immunooncology, regenerative medicine and other rare diseases. The company has a clinical-stage programme, CTX001 in sickle cell disease and beta-thalassemia, with promising preliminary results so far. Furthermore, the company is investigating three distinct CRISPR-Cas9-modified CAR-T cell therapies. The company is co-founded by Dr. Emanuelle Charpentier and holds multiple important patents within the gene-editing space.
Tags
Press Releases
Related News and Updates
Clinical Trials
Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05477563)
Sponsors:
Vertex Pharmaceuticals Incorporated
Sponsors:
Vertex Pharmaceuticals Incorporated
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT04208529)
Sponsors:
Vertex Pharmaceuticals
Sponsors:
Vertex Pharmaceuticals
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
